<DOC>
	<DOCNO>NCT02317458</DOCNO>
	<brief_summary>This study design evaluate efficacy safety C3BS-CQR-1 treatment patient chronic heart failure secondary ischemic cardiomyopathy .</brief_summary>
	<brief_title>Congestive Heart Failure Cardiopoietic Regenerative Therapy ( CHART-2 ) Trial - THE CHART-2 TRIAL</brief_title>
	<detailed_description>Patients chronic heart failure secondary ischemic cardiomyopathy standard care screen per protocol inclusion exclusion criterion . Enrolled patient randomize 1:1 ratio either standard care C3BS-CQR-1 injection ( treatment group ) standard care undergo sham procedure ( control group ) . Patients randomized treatment group , C3BS-CQR-1 production meet release criterion , undergo endoventricular injection C3BS-CQR-1 use injection catheter .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Age ≥ 18 &lt; 80 year . 2 . Systolic dysfunction LVEF ≤ 35 % assessed echocardiography . 3 . Ischemic heart failure ineligible revascularization . Ischemic heart failure define history myocardial infarction evidence clinically significant coronary disease associate LV systolic dysfunction lead HF . The patient must candidate revascularization judgment investigator , base absence unstable coronaryrelated symptom either noninvasive testing coronary angiography within 24 month prior screen . 4 . Total MLHFQ score &gt; 30 . 5 . Ability perform SixMinute Walk Test &gt; 100 ≤ 375 m. 6 . History hospitalization HF within 12 month prior screen treatment outpatient clinic intravenous therapy ( include vasodilator , positive inotropic agent , vasopressor diuretic ) worsen HF within 12 month prior screen . Be must diagnose within previous 12 month NYHA class III IV INTERMACS class 4 , 5 , 6 7 , time inclusion , must least NYHA class II great . If NYHA class II , 2 HF worsen event NTProBNP &gt; 1000 pg/mL require hospitalization outpatient IV therapy prior 12 month require . 7 . Use ACE inhibitor and/or ARB sacubitril/valsartan ( Entresto™ ) ; beta blocker , least 3 month prior screen visit , unless intolerant contraindicate . 8 . Stable dose ACE inhibitor ARB sacubitril/valsartan ( Entresto™ ) beta blocker , aldosterone blocker , diuretic least one month prior screen visit , define ≤50 % change total dose agent . 9 . Willing able give write informed consent . 1 . Women pregnant , confirm positive urine serum hCG laboratory test screening . 2 . Women childbearing potential without negative serum urine pregnancy test screen practice reliable form birth control . Women postmenopausal ( 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL 6 week postsurgical bilateral oophorectomy ) surgically sterile consider childbearing potential . Reliable contraception include surgical sterilization , hormonal contraception , doublebarrier method . 3 . Men refuse exercise reliable form contraception unless partner unable conceive . 4 . Acute coronary syndrome lead myocardial infarction unstable angina within 90 day screen . 5 . Percutaneous coronary intervention ( PCI ) within 90 day prior screen , CABG surgery within 180 day prior screen . 6 . Patient cardiac transplant list previously receive solid organ transplant . 7 . Previously underwent cardiac surgery remodel procedure , leave ventricular assist device placement cardiomyoplasty . This exclusion apply patient underwent ventricularplasty without placement device &gt; 1 year ago . 8 . Patient undergone cardiac resynchronization therapy ( CRT ) within 6 month ( 180 day ) prior screen . 9 . Severe uncontrolled HF require need intravenous diuretic inotropic support within 1 month prior screen . 10 . Inability perform SixMinute Walk Test due physical limitation HF include : 1 . Severe peripheral vascular disease 2 . Severe pulmonary disease chronic obstructive pulmonary disease ( COPD ) FEV1 &lt; 30 % predict 3 . Orthopedic limitation , severe muscular disease , joint muscular disease neurological disorder ( old stroke neuropathy ) limit ability walk 6 minute . 11 . Dependence chronic oral steroid therapy . 12 . Stroke transient ischemic attack lead limitation low extremity occur within 180 day prior screen . 13 . Active myocarditis , constrictive pericarditis , restrictive , hypertrophic congenital cardiomyopathy . 14 . BMI &lt; 19 &gt; 40 kg/m2 . 15 . Left ventricular thrombus . 16 . Left ventricular wall thickness &lt; 8mm visualized 50 % LV , define `` LV nogo zone 17 . LV aneurysm candidate surgical aneurysmectomy . 18 . Sustained VT VF lead AICD therapy ( shock ) within 3 month prior screen . 19 . Primary valvular disease ≥ moderate degree , include mitral aortic stenosis ( aortic valve area &lt; 1.5 cm2 ) regurgitation . Secondary mitral tricuspid regurgitation due LV dilatation exclude 20 . Prosthetic valve aortic mitral position , prior MitraClip placement . 21 . Chronic infection active malignancy . 22 . Compromised renal function reflect serum creatinine level &gt; 2,0 mg/dL ( &gt; 0.177 mmol/l ) currently dialysis . 23 . Hematocrit &lt; 28 % . 24 . Atherosclerosis and/or tortuosity aorta , iliac femoral artery degree could impede preclude safe retrograde passage delivery catheter , include untreated aneurysm aorta . 25 . Chronic immunosuppressive therapy due inflammatory systemic disease . 26 . Patient test positive HIV 1 2 , Hepatitis B C , HTLV 1 syphilis ( detailed Section 19.1 ) . 27 . Exposure previous experimental cell angiogenic therapy and/or myocardial laser therapy and/or therapy another investigational drug within 60 day prior screen enrollment concurrent study may confound result study . 28 . Known drug alcohol dependence factor interfere study conduct interpretation result opinion investigator suitable participate . 29 . Any illness CHF might reduce life expectancy le 2 year screen . 30 . Known relevant allergy and/or hypersensitivity Dextran plasma volume expanders ( include Gentran , Hyskon Macrodex ) , Bovine Serum Albumin ( BSA ) albumin animal origin . 31 . Known severe allergy cardiac radiological contrast mixture . 32 . Required dosage cardiopoietic cell reach</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>